NCT04915144 2023-02-21177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsBritish Columbia Cancer AgencyPhase 2 Withdrawn
NCT00227773 2015-10-08Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsEastern Cooperative Oncology GroupPhase 2 Withdrawn